2. Academic Validation
  3. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

  • Cancers (Basel). 2023 May 24;15(11):2899. doi: 10.3390/cancers15112899.
Shenduo Li 1,  Guilherme Sacchi de Camargo Correia 1,  Jing Wang 2,  Rami Manochakian 1,  Yujie Zhao 1,  Yanyan Lou 1
Affiliations

Affiliations

  • 1 Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
  • 2 Department of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
PMID: 37296863 DOI: 10.3390/cancers15112899
Abstract

Lung Cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung Cancer (NSCLC) is the most common type and is still incurable for most patients at the advanced stage. Targeted therapy is an effective treatment that has significantly improved survival in NSCLC patients with actionable mutations. However, therapy resistance occurs widely among patients leading to disease progression. In addition, many oncogenic driver mutations in NSCLC still lack targeted agents. New drugs are being developed and tested in clinical trials to overcome these challenges. This review aims to summarize emerging targeted therapy that have been conducted or initiated through first-in-human clinical trials in the past year.

Keywords

EGFR; NSCLC; clinical trial; first-in-human; phase I/II; targeted therapy.

Figures
Products